Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cardiology Reviews
  4. Volume 21, Issue 3
  5. Article
Volume 21, Issue 3
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Introduction

Chronic ischemic heart failure is a major global health issue despite advancements in therapy. Stem cell (SC) therapy has emerged as a potential treatment, but its effectiveness remains uncertain. This study aimed to systematically review and meta-analyze the current evidence on SC therapy's efficacy.

Methods

We conducted a comprehensive literature search in PubMed, Embase, and Cochrane databases up to April 2024. We included randomized controlled trials (RCTs) with blinded designs, focusing on patients with heart failure with reduced ejection fraction (HFrEF) treated with mesenchymal stem cells compared to placebo or sham interventions percutaneous endomyocardial catheter systems. Data extraction, performed independently by two authors, focused on safety and efficacy variables. The meta-analysis used a random-effects model, with sensitivity analyses to address study heterogeneity.

Results

Twenty studies were included in the meta-analysis. Significant improvements were observed in the stem cell group for left ventricular end-systolic volume (LVESV) (pooled effect size -7.59, 95% CI [-12.28 to -2.89], 0.002) and stress SPECT outcomes (pooled effect size -5.33, 95% CI [-6.73 to -3.93], <0.00001). Sensitivity analysis reduced heterogeneity in left ventricular end-diastolic function (LVEDF) (0.01, I2=54%) and revealed a significant benefit for stem cell therapy (pooled effect size -3.87, 95% CI [-6.77 to -0.97], 0.009). No significant effects were observed for left ventricular ejection fraction (LVEF) or myocardial oxygen consumption (MVO2). Functional improvements in New York Heart Association (NYHA) classification were noted (OR=4.22, 95% CI (1.14-15.68), 0.03), though no significant differences were found in safety outcomes, including major cardiovascular events, mortality, or rehospitalization rates.

Conclusion

Transendocardial SC therapy shows promise in improving certain cardiac parameters, though its impact on LVEF and MVO2 remains inconclusive, indicating the need for further research.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X353157250115105436
2025-01-27
2025-06-18

  • From This Site

    /content/journals/ccr/10.2174/011573403X353157250115105436
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. McMurrayJ.J.V. AdamopoulosS. AnkerS.D. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.Eur. Heart J.201233141787184710.1093/eurheartj/ehs104 22611136
     [Google Scholar]
  2. BenjaminE.J. MuntnerP. AlonsoA. Heart disease and stroke statistics-2019 update: A report from the American Heart Association.Circulation201913910e56e52810.1161/CIR.0000000000000659 30700139
     [Google Scholar]
  3. ZiaeianB. FonarowG.C. Epidemiology and aetiology of heart failure.Nat. Rev. Cardiol.201613636837810.1038/nrcardio.2016.25 26935038
     [Google Scholar]
  4. PonikowskiP. VoorsA.A. AnkerS.D. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur. Heart J.201637272129220010.1093/eurheartj/ehw128 27206819
     [Google Scholar]
  5. SapnaF.N.U. RaveenaF.N.U. ChandioM. Advancements in heart failure management: A comprehensive narrative review of emerging therapies.Cureus20231510e4648610.7759/cureus.46486 37927716
     [Google Scholar]
  6. KarantalisV. HareJ.M. Use of mesenchymal stem cells for therapy of cardiac disease.Circ. Res.201511681413143010.1161/CIRCRESAHA.116.303614 25858066
     [Google Scholar]
  7. KastrupJ. MygindN.D. QayyumA.A. MathiasenA.B. Haack-SørensenM. EkblondA. Mesenchymal stromal cell therapy in ischemic heart disease.Scand. Cardiovasc. J.2016505-629329910.1080/14017431.2016.1210213 27380735
     [Google Scholar]
  8. GyöngyösiM. WojakowskiW. LemarchandP. Meta-analysis of cell-based cardiac studies (ACCRUE) in patients with acute myocardial infarction based on individual patient data.Circ. Res.201511681346136010.1161/CIRCRESAHA.116.304346 25700037
     [Google Scholar]
  9. FisherS.A. DoreeC. MathurA. TaggartD.P. Martin-RendonE. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.Cochrane Libr.2016201612CD00788810.1002/14651858.CD007888.pub3 28012165
     [Google Scholar]
  10. FanM. HuangY. ChenZ. Efficacy of mesenchymal stem cell therapy in systolic heart failure: A systematic review and meta-analysis.Stem Cell Res. Ther.201910115010.1186/s13287‑019‑1258‑1 31151406
     [Google Scholar]
  11. FuH. ChenQ. Mesenchymal stem cell therapy for heart failure: A meta-analysis.Herz202045655756310.1007/s00059‑018‑4762‑7 30341444
     [Google Scholar]
  12. JayarajJ.S. JanapalaR.N. QaseemA. Efficacy and safety of stem cell therapy in advanced heart failure patients: A systematic review with a meta-analysis of recent trials between 2017 and 2019.Cureus2019119e558510.7759/cureus.5585 31696004
     [Google Scholar]
  13. LaluM.M. MazzarelloS. ZlepnigJ. Safety and efficacy of adult stem cell therapy for acute myocardial infarction and ischemic heart failure (safecell heart): A systematic review and meta-analysis.Stem Cells Transl. Med.201871285786610.1002/sctm.18‑0120 30255989
     [Google Scholar]
  14. HareJ.M. TraverseJ.H. HenryT.D. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.J. Am. Coll. Cardiol.200954242277228610.1016/j.jacc.2009.06.055 19958962
     [Google Scholar]
  15. ChenS. FangW. YeF. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction.Am. J. Cardiol.2004941929510.1016/j.amjcard.2004.03.034 15219514
     [Google Scholar]
  16. Krishna MohanG.V. TirumandyamG. VemulapalliH.S. VajjeJ. AsifH. SaleemF. Mesenchymal stem cell therapy for a better prognosis of heart failure: A systematic review and meta-analysis of randomized controlled trials.Cureus2023158e4303710.7759/cureus.43037 37674948
     [Google Scholar]
  17. Haack-SorensenM. BindslevL. MortensenS. FriisT. KastrupJ. The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use.Cytotherapy20079432833710.1080/14653240701322235 17573608
     [Google Scholar]
  18. PerinE.C. SilvaG.V. AssadJ.A.R. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction.J. Mol. Cell. Cardiol.200844348649510.1016/j.yjmcc.2007.09.012 18061611
     [Google Scholar]
  19. RigolM. SolanesN. FarréJ. Effects of adipose tissue-derived stem cell therapy after myocardial infarction: Impact of the route of administration.J. Card. Fail.201016435736610.1016/j.cardfail.2009.12.006 20350704
     [Google Scholar]
  20. GolpanianS. WolfA. HatzistergosK.E. HareJ.M. Rebuilding the damaged heart: Mesenchymal stem cells, cell-based therapy, and engineered heart tissue.Physiol. Rev.20169631127116810.1152/physrev.00019.2015 27335447
     [Google Scholar]
  21. HeldmanA.W. DiFedeD.L. FishmanJ.E. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial.JAMA20143111627310.1001/jama.2013.282909 24247587
     [Google Scholar]
  22. BartunekJ. BehfarA. DolatabadiD. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem cell therapy in heart failure) multicenter randomized trial with lineage-specified biologics.J. Am. Coll. Cardiol.201361232329233810.1016/j.jacc.2013.02.071 23583246
     [Google Scholar]
  23. BolliR. MitraniR.D. HareJ.M. A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: The CCTRN CONCERT‐HF trial.Eur. J. Heart Fail.202123466167410.1002/ejhf.2178 33811444
     [Google Scholar]
  24. ChoudhuryT. MozidA. HamshereS. An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: The REGENERATE‐IHD clinical trial.Eur. J. Heart Fail.201719113814710.1002/ejhf.676 27790824
     [Google Scholar]
  25. QayyumA.A. van KlarenboschB. FrljakS. Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the science trial.Eur. J. Heart Fail.202325457658710.1002/ejhf.2772 36644821
     [Google Scholar]
  26. DibN. DinsmoreJ. LababidiZ. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study).JACC Cardiovasc. Interv.20092191610.1016/j.jcin.2008.11.003 19463392
     [Google Scholar]
  27. HenryT.D. PepineC.J. LambertC.R. The Athena trials: Autologous adipose‐derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction.Catheter. Cardiovasc. Interv.201789216917710.1002/ccd.26601 27148802
     [Google Scholar]
  28. MathiasenA.B. QayyumA.A. JørgensenE. Bone marrow‐derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: Final 4‐year follow‐up of the MSC‐HF trial.Eur. J. Heart Fail.202022588489210.1002/ejhf.1700 31863561
     [Google Scholar]
  29. DuckersH. HoutgraafJ. HehrleinC. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: The SEISMIC trial.EuroIntervention20116780581210.4244/EIJV6I7A139 21252013
     [Google Scholar]
  30. PokushalovE. RomanovA. ChernyavskyA. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: A randomized study.J. Cardiovasc. Transl. Res.20103216016810.1007/s12265‑009‑9123‑8 20560030
     [Google Scholar]
  31. PerinE.C. WillersonJ.T. PepineC.J. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial.JAMA2012307161717172610.1001/jama.2012.418 22447880
     [Google Scholar]
  32. SantosoT. SiuC.W. IrawanC. Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: A randomized placebo-controlled trial (END-HF).J. Cardiovasc. Transl. Res.20147654555210.1007/s12265‑014‑9580‑6 25079593
     [Google Scholar]
  33. QayyumA.A. MouridsenM. NilssonB. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.ESC Heart Fail.20231021170118310.1002/ehf2.14281 36638837
     [Google Scholar]
  34. TeerlinkJ.R. MetraM. FilippatosG.S. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: Results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) study.Eur. J. Heart Fail.201719111520152910.1002/ejhf.898 28560782
     [Google Scholar]
  35. PerinE.C. SilvaG.V. ZhengY. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure.Am. Heart J.2012163341542110.1016/j.ahj.2011.11.020 22424012
     [Google Scholar]
  36. PerinE.C. Sanz-RuizR. SánchezP.L. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The precise trial.Am. Heart J.201416818895.e210.1016/j.ahj.2014.03.022 24952864
     [Google Scholar]
  37. PerinE.C. BorowK.M. SilvaG.V. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure.Circ. Res.2015117657658410.1161/CIRCRESAHA.115.306332 26148930
     [Google Scholar]
  38. PerinE.C. BorowK.M. HenryT.D. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure.J. Am. Coll. Cardiol.202381984986310.1016/j.jacc.2022.11.061 36858705
     [Google Scholar]
  39. PerinE.C. SilvaG.V. HenryT.D. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF).Am. Heart J.2011161610781087.e310.1016/j.ahj.2011.01.028 21641354
     [Google Scholar]
  40. PatelA.N. HenryT.D. QuyyumiA.A. Ixmyelocel-T for patients with ischaemic heart failure: A prospective randomised double-blind trial.Lancet2016387100362412242110.1016/S0140‑6736(16)30137‑4 27059887
     [Google Scholar]
  41. WilliamsA.R. SuncionV.Y. McCallF. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling.J. Am. Heart Assoc.201323e00014010.1161/JAHA.113.000140 23686370
     [Google Scholar]
  42. TompkinsB.A. RiegerA.C. FloreaV. Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy.J. Am. Heart Assoc.2018714e00846010.1161/JAHA.117.008460 30005555
     [Google Scholar]
  43. HareJ.M. DiFedeD.L. RiegerA.C. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy.J. Am. Coll. Cardiol.201769552653710.1016/j.jacc.2016.11.009 27856208
     [Google Scholar]
  44. JeevananthamV. ButlerM. SaadA. Abdel-LatifA. Zuba-SurmaE.K. DawnB. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: A systematic review and meta-analysis.Circulation2012126555156810.1161/CIRCULATIONAHA.111.086074 22730444
     [Google Scholar]
  45. KandalaJ. UpadhyayG.A. PokushalovE. WuS. DrachmanD.E. SinghJ.P. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy.Am. J. Cardiol.2013112221722510.1016/j.amjcard.2013.03.021 23623290
     [Google Scholar]
  46. VarzidehF. GambardellaJ. KansakarU. JankauskasS.S. SantulliG. Molecular mechanisms underlying pluripotency and self-renewal of embryonic stem cells.Int. J. Mol. Sci.2023249838610.3390/ijms24098386 37176093
     [Google Scholar]
  47. van der SpoelT.I.G. GathierW.A. KoudstaalS. Autologous mesenchymal stem cells show more benefit on systolic function compared to bone marrow mononuclear cells in a porcine model of chronic myocardial infarction.J. Cardiovasc. Transl. Res.20158739340310.1007/s12265‑015‑9643‑3 26382088
     [Google Scholar]
  48. ShenT. XiaL. DongW. A systematic review and meta-analysis: Safety and efficacy of mesenchymal stem cells therapy for heart failure.Curr. Stem Cell Res. Ther.202116335436510.2174/1574888X15999200820171432 32867655
     [Google Scholar]
  49. LiX. HackerM. Molecular imaging in stem cell-based therapies of cardiac diseases.Adv. Drug Deliv. Rev.2017120718810.1016/j.addr.2017.07.012 28734900
     [Google Scholar]
  50. JeevananthamV. ButlerM. SaadA. Abdel-LatifA. Zuba-SurmaE.K. DawnB. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters/clinical perspective.Circulation2012126555156810.1161/CIRCULATIONAHA.111.086074 22730444
     [Google Scholar]
  51. van der SpoelTIG Jansen of LorkeersSJ AgostoniP. Human relevance of pre-clinical studies in stem cell therapy: Systematic review and meta-analysis of large animal models of ischaemic heart disease.Cardiovasc. Res.201191464965810.1093/cvr/cvr113 21498423
     [Google Scholar]
  52. MushtaqM. DiFedeD.L. GolpanianS. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): A phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.J. Cardiovasc. Transl. Res.20147976978010.1007/s12265‑014‑9594‑0 25354998
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X353157250115105436
Loading
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Curr. Cardiol. Rev. 21, E1573403X353157 (2025); https://doi.org/10.2174/011573403X353157250115105436
/content/journals/ccr/10.2174/011573403X353157250115105436
/content/journals/ccr/10.2174/011573403X353157250115105436
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): cardiac parameters; chronic ischemic heart failure; left ventricular function; mesenchymal stem cell; myocardial perfusion; Stem cell therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test